About this trial
This clinical trial evaluates the effectiveness of focal ablation with either focal cryotherapy or high intensity frequency ultrasound for the treatment of men with localized prostate cancer. Focal cryotherapy kills tumor cells by freezing them. High intensity frequency ultrasound uses highly focused ultrasound waves to produce heat and destroy tumor cells.
Eligibility criteria
Qualifiers
Ability to understand and willingness to sign an informed consent form
Clinically localized grade group 1, 2, or 3 prostate cancer and unilateral magnetic resonance imaging (MRI) visible lesion(s). Up to 3 lesions will be allowed for focal treatment
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Karnofsky ≥ 70%)
Patients ≥ 18 years of age at time of consent
Disqualifiers
Nodal or distant metastases
Prior treatment for prostate cancer
Anticipated treatment with any cancer intervention, including radiation, hormonal therapy or surgery ≤ 6 months prior to focal therapy in this study
Known contraindications to general anesthesia
Trial design
Treatments tested in this trial
- Cryosurgery
- High-Intensity Focused Ultrasound Ablation
- Survey Administration
Treatment groups
Locations
1Sponsors and collaborators
University of California, Davis
Lead sponsor
National Cancer Institute (NCI)
Collaborator